연구동향 분석

Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty

이지우 김형진 최윤미 강희숙 김순기 전용훈 이지은 2014년

논문상세정보
인용/피인용
' Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 부인과, 산과학, 소아과학
  • centralprecociouspuberty
  • drug-related side effects and adverse reactions
  • leuprolide
  • triptorelin
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
491 0

0.0%

' Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty' 의 참고문헌

  • 한국 청소년의 성성숙 시기 및 장기간의 초경연령 추세분석
    박미정 Korean Journal of Pediatrics 49 6 610-616 [2006]
  • 진성성조숙증 환아에서 다른 두 종류의 생식샘자극호르몬방출호르몬 작용제 치료에 의해 발생한 무균 농양
    김종문 Annals of Pediatirc Endocrinology & Metabolism 17 3 184-188 [2012]
  • Two-year results of treatment with depot leuprolide acetate for central precocious puberty
    Neely EK J Pediatr 121 634-640 [1992]
  • The epidemiology of slipped capital femoral epiphysis: an update
    Lehmann CL J Pediatr Orthop 26 286-290 [2006]
  • Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty
    Johnson SR J Paediatr Child Health 48 E136-E139 [2012]
  • Slipped capital femoral epiphysis update
    Gholve PA Curr Opin Pediatr 21 39-45 [2009]
  • Slipped capital femoral epiphysis during the treatment of precocious puberty with a gonadotropinreleasing hormone-agonist: aetiological considerations
    Yamato F Eur J Pediatr 164 173-174 [2005]
  • Slipped capital femoral epiphysis associated with endocrine disorders
    Loder RT J Pediatr Orthop 15 349-356 [1995]
  • Slipped capital femoral epiphyses associated with the withdrawal of a gonadotrophin releasing hormone
    van Puijenbroek E BMJ 328 1353- [2004]
  • Second symposium on the definition and management of anaphylaxis:summary report: Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
    Sampson HA J Allergy Clin Immunol 117 391-397 [2006]
  • Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty
    Sorensen K Horm Res Paediatr 77 137-145 [2012]
  • Pathogenesis of slipped capital femoral epiphysis:current concepts
    Weiner D J Pediatr Orthop B 5 67-73 [1996]
  • Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty
    Inman M Horm Res Paediatr 80 64-68 [2013]
  • Lovell and Winter’s pediatrics
    Douglas KK 993-1005 [1996]
  • Local reactions to luteinizing hormone releasing hormone analog therapy
    Tonini G J Pediatr 126 159-160 [1995]
  • Local reactions to depot leuprolide therapy for central precocious puberty
    Manasco PK J Pediatr 123 334-335 [1993]
  • Epidemiology and demographics of slipped capital femoral epiphysis in Korea: a multicenter study by the Korean Pediatric Orthopedic Society
    Song KS J Pediatr Orthop 29 683-686 [2009]
  • Diagnostic work-up of 449 consecutive girls who were referred to be evaluated for precocious puberty
    Mogensen SS J Clin Endocrinol Metab 96 1393-1401 [2011]
  • Can GnRH-agonist treatment cause slipped capital femoral epiphysis?
    Kempers MJ J Pediatr Endocrinol Metab 14 729-734 [2001]
  • Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer
    Grant JP Jr Clin Genitourin Cancer 5 284-286 [2007]
  • Anaphylactic reaction to different gonadotropin-releasing hormone agonists for the treatment of endometriosis
    Luchinger AB Am J Med Sci 341 240-242 [2011]